Previous close | 0.0300 |
Open | 0.0700 |
Bid | 0.0000 |
Ask | 0.0600 |
Strike | 70.00 |
Expiry date | 2024-06-21 |
Day's range | 0.0700 - 0.0700 |
Contract range | N/A |
Volume | |
Open interest | 130 |
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.